A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. / Naimi, R M; Madsen, K B; Askov-Hansen, C; Brandt, C F; Hartmann, B; Holst, Jens Juul; Mortensen, P B; Jeppesen, P B.

In: Regulatory Peptides, Vol. 184, No. 10, 10.06.2013, p. 47-53.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Naimi, RM, Madsen, KB, Askov-Hansen, C, Brandt, CF, Hartmann, B, Holst, JJ, Mortensen, PB & Jeppesen, PB 2013, 'A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients', Regulatory Peptides, vol. 184, no. 10, pp. 47-53. https://doi.org/10.1016/j.regpep.2013.03.023

APA

Naimi, R. M., Madsen, K. B., Askov-Hansen, C., Brandt, C. F., Hartmann, B., Holst, J. J., ... Jeppesen, P. B. (2013). A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. Regulatory Peptides, 184(10), 47-53. https://doi.org/10.1016/j.regpep.2013.03.023

Vancouver

Naimi RM, Madsen KB, Askov-Hansen C, Brandt CF, Hartmann B, Holst JJ et al. A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. Regulatory Peptides. 2013 Jun 10;184(10):47-53. https://doi.org/10.1016/j.regpep.2013.03.023

Author

Naimi, R M ; Madsen, K B ; Askov-Hansen, C ; Brandt, C F ; Hartmann, B ; Holst, Jens Juul ; Mortensen, P B ; Jeppesen, P B. / A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. In: Regulatory Peptides. 2013 ; Vol. 184, No. 10. pp. 47-53.

Bibtex

@article{7264c92fe3544ac4bc7b801eee696b2e,
title = "A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients",
abstract = "Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.",
author = "Naimi, {R M} and Madsen, {K B} and C Askov-Hansen and Brandt, {C F} and B Hartmann and Holst, {Jens Juul} and Mortensen, {P B} and Jeppesen, {P B}",
note = "Copyright {\circledC} 2013 Elsevier B.V. All rights reserved.",
year = "2013",
month = "6",
day = "10",
doi = "10.1016/j.regpep.2013.03.023",
language = "English",
volume = "184",
pages = "47--53",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "10",

}

RIS

TY - JOUR

T1 - A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

AU - Naimi, R M

AU - Madsen, K B

AU - Askov-Hansen, C

AU - Brandt, C F

AU - Hartmann, B

AU - Holst, Jens Juul

AU - Mortensen, P B

AU - Jeppesen, P B

N1 - Copyright © 2013 Elsevier B.V. All rights reserved.

PY - 2013/6/10

Y1 - 2013/6/10

N2 - Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.

AB - Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.

U2 - 10.1016/j.regpep.2013.03.023

DO - 10.1016/j.regpep.2013.03.023

M3 - Journal article

C2 - 23501043

VL - 184

SP - 47

EP - 53

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 10

ER -

ID: 45842300